Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, Anna Tomiak, Alastair P Greystoke, Anthony M Joshua, Hendrik-Tobias Arkenau, Lajos Géczi, Javier Garcia-Corbacho, Luis G Paz-Ares, Syed A Hussain, Lubos Petruželka, Angelo Delmonte, Colombe Chappey, Joanna C Masters, Elisabete Michelon, Danielle A Murphy, Sandrine Mwewa, Rossano Cesari, Bernard Doger de Speville
INTRODUCTION: Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase 1b/2 JAVELIN Chemotherapy Medley trial evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or nonsmall cell lung cancer (NSCLC). PATIENTS AND METHODS: Avelumab 800 mg or 1200 mg was administered continuously every 3 weeks (Q3W) with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC...
April 26, 2024: Cancer Res Commun